Document Detail


Interventions in acute myocardial infarction.
MedLine Citation:
PMID:  2407374     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Results of multiple studies have amply verified the benefit of urgent coronary revascularization for patients who have acute myocardial infarction (MI). Currently, intravenous thrombolytic therapy is the treatment of choice for many patients, especially those 75 years old or younger who present within 6 hours of symptom onset and who are without contraindications to thrombolytic therapy. Some patients treated within 6-24 hours of symptom onset may also benefit, but this remains unproven. The thrombolytic agents currently in use or being extensively evaluated include streptokinase, urokinase, tissue-type plasminogen activator (t-PA), anisoylated plasminogen streptokinase activator complex (APSAC or anistreplase), and single-chain urokinase-type plasminogen activator (scu-PA). The agent t-PA has the potential advantage of being clot selective and, thereby, relatively fibrinogen sparing, and its efficacy in terms of restoration of vessel patency is less dependent on the time of administration as compared with that of streptokinase and urokinase. It is not yet known whether this will translate into improved patient survival as compared with that achieved by the less-expensive agents streptokinase and APSAC. Treatment regimens of combination thrombolytic agents have been developed, but the optimal combinations have not yet been determined. Patients who are in cardiogenic shock and those in whom thrombolytic therapy is contraindicated can probably benefit from angioplasty or bypass surgery. Results of several studies have suggested that immediate angioplasty after successful thrombolysis is not beneficial; however, the potential benefit of angioplasty or bypass surgery for failed thrombolytic therapy is yet to be evaluated. Although many advances have been made, further research is clearly needed in the area of reperfusion.
Authors:
S G Ellis
Related Documents :
3278574 - Combination of calcium channel blocker and thrombolytic therapy in acute myocardial inf...
1806764 - Strategies for administration of tissue plasminogen activator.
3521234 - Coronary thrombolytic therapy: state of the art.
2646894 - Thrombolytic agents in early myocardial infarction.
12635054 - Association of sex with perioperative mortality and morbidity after carotid endarterect...
15229734 - Determinants of long-term survival after isolated aortic valve replacement: a 10- to 17...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Circulation     Volume:  81     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1990 Mar 
Date Detail:
Created Date:  1990-04-06     Completed Date:  1990-04-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  IV43-50     Citation Subset:  AIM; IM    
Affiliation:
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary
Coronary Artery Bypass
Drug Combinations
Evaluation Studies as Topic
Fibrinolytic Agents / adverse effects,  therapeutic use
Humans
Myocardial Infarction / physiopathology,  therapy*
Myocardial Reperfusion / standards
Postoperative Care
Time Factors
Chemical
Reg. No./Substance:
0/Drug Combinations; 0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Quantitative and qualitative ST segment monitoring during and after percutaneous transluminal corona...
Next Document:  Myocardial reperfusion injury. Histopathological effects of perfluorochemical.